{"id":"amrubicin-hydrocloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL1186894","moleculeType":"Small molecule","molecularWeight":"483.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amrubicin is a semi-synthetic anthracycline derivative that binds to DNA and inhibits topoisomerase II, an enzyme essential for DNA replication and transcription. By preventing the re-ligation of DNA breaks, it causes accumulation of DNA damage and triggers apoptosis in rapidly dividing cancer cells. It is structurally related to doxorubicin but has enhanced activity against certain tumor types.","oneSentence":"Amrubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents the religation of DNA strands, leading to cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:30.662Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT01207011","phase":"PHASE3","title":"Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2010-10","conditions":"Lung Cancer","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Amrubicin hydrocloride","genericName":"Amrubicin hydrocloride","companyName":"Sumitomo Pharma Co., Ltd.","companyId":"sumitomo-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amrubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents the religation of DNA strands, leading to cell death. Used for Small cell lung cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}